IL17A and psoriasis: Inflammation in psoriasis patients is effectively treated with biological agents – tumor necrosis factor-α (TNF-α) inhibitors such as infliximab, adalimumab, and etanercept; ustekinumab (interleukin [IL]-12/23 inhibitor), and secukinumab (IL-17 inhibitor) (4).